Medshine Discovery Inc.

Guangdong Raynovent Biotech Co., Ltd.

Helioeast Science & Technology Co., Ltd.

Merck Sharp + Dohme Corp.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Merck Canada Inc.

Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

Jiangsu Kanion Pharmaceutical Co., Ltd.

Guangdong Zhongsheng Pharmaceutical Co., Ltd

Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd.

China Resources Pharmaceutical Holdings Company Limited

Jumbo Drug Bank Co., Ltd.

Guizhou Inochini Technology Co., Ltd

Helioeast Pharmaceutical Co., Ltd.

Shijiazhuang Sagacity New Drug Development Company, Ltd.

Lingyun Wu

Shuhui Chen

Jian Li

Peng Zhang

Lele Zhao

Fang Liu

Chaofeng Long

Xiaoxin Chen

Zhuowei Liu

Zhaoguo Chen

Cailin Wang

Zheming Xiao

Jianjun Sun

Xu You

Charles Z Ding

Jun Yin

Lihong Hu

Yuanshan Yao

Xile Liu

XiaWei Wei

Peng Yang

Xing Liu

Michael D Altman

Yi Chen

Zheng Wang

Alan B Northrup

Daniel Guay

Guoping Hu

Michelle R Machacek

Yves Ducharme

Solomon D Kattar

Ryan D Otte

Andrew M Haidle

Michael Hale Reutershan

John Michael Ellis

Matthew Christopher

Jonathan B Grimm

Weidong Li

Jun Zhao

Anthony Donofrio

Kaleen Konrad Childers

Kerrie Spencer

Christian Beaulieu

Brandon D Cash

Wen Jiang

Chen Zhang

Eric Thomas Romeo

Lijuan Chen

Xiongbin Xu

Ning Zhao

Brendan O'Boyle

Dilrukshi Vitharana

Xiawei Wei

Yizhi Liu

Wei Zheng

Haiwen Wan

Ning Jiang

Wei Pan

Yandong Wang

Xinming Du

Ru Feng

Zhen Zhan

Qiuyan Wang

Chunyan Jiang

Jian Ge

Li Zhang

Brendan O' Boyle

Disclosed are pyrrolotriazine compounds which act as a mitogen-activated protein kinase interacting kinase (MNK) inhibitor, and the use thereof in the preparation of a mitogen-activated protein kinase interacting kinase inhibitor drug. Specifically disclosed are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof.

Pyrrolotriazine compounds acting as MNK inhibitor

Disclosed are an acetophenone oxime compound and a preparation method therefor, and specifically disclosed are a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.

Acetophenone oxime compound and application thereof

Disclosed are a series of isoquinolone derivatives as ROCK protein kinase inhibitors and uses thereof in preparing medicaments for ROCK protein kinase inhibitor-related glaucoma or ocular hypertension diseases. Specially, disclosed are a compound of formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

Isoquinolinone derivatives serving as rock protein kinase inhibitors and use thereof

Disclosed is a class of porcupine inhibitors, specifically a compound as represented by formula (I), and a pharmaceutically acceptable salt or an isomer thereof.

Compound as porcupine inhibitor and use thereof

Provided are a compound III serving as an LSD1 inhibitor and a crystal form thereof, as well as use of the compound and the crystal form thereof in preparation of a medicament for treating an LSD1 related disease.

Salt of LSD1 inhibitor and a polymorph thereof

Disclosed are a series of benzo 2-azaspiro[4.4]nonane compounds, and specifically disclosed are a compound as represented by formula (P) or a pharmaceutically acceptable salt thereof.

Benzo 2-azaspiro[4.4]nonane compound and use thereof

Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kinase inhibitors. Specifically, disclosed are hydrochloride and acetate of compounds of formula (I) and crystal forms thereof, as well as application of the salt types and the crystal forms in preparation of RHO inhibitor drugs.

Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kinase inhibitors

Provided is a cyclopropylamine compound as lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in preparation of drug for treating diseases associated with LSD1. The cyclopropylamine compound is a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof. 

Cyclopropylamine compound as LSD1 inhibitor and use thereof

Disclosed are a class of pyrazole compounds and applications thereof in the preparation of a medicament for treating related diseases. Specifically, related are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof. 

Pyrazole compounds as LSD1 inhibitors and applications thereof

Provided are a crystal form of a tricyclic compound and a preparation process thereof. Also provided is an application of the crystal form in preparing a drug for treating a disease related to a sphingosine-1-phosphate subtype 1 (S1P1) receptor. 

Crystal and salt forms of tricyclic compound and preparation process thereof

A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention also provides an application of the same in preparing a drug for treating an LSD1-related disease. 

LSD1 inhibitor and preparation method and application thereof

Disclosed is a class of new aryl-phosphorus-oxygen compounds as shown in formula (I) as EGFR kinase inhibitors, and pharmaceutically acceptable salts thereof. 

Aryl-phosphorus-oxygen compound as EGFR kinase inhibitor

Hydroxyl purine compounds represented by formula (I), tautomers or pharmaceutically acceptable salts thereof, and applications thereof as PDE2 or TNF-&#x3b1; inhibitors.

Hydroxyl purine compounds and applications thereof

The invention relates to a benzopyrazole compound used as RHO kinase inhibitor, a pharmaceutical composition and uses thereof for preparing an RHO kinase inhibiting drug, and more specifically to said compound of formula (I-1), a pharmaceutically acceptable salt and isomer thereof. 

Benzopyrazole compound used as RHO kinase inhibitor

The present invention relates to a class of tricyclic compounds and an application thereof as a sphingosine 1-phosphate type 1 (S1P1) receptor agonist. The invention specifically relates to a compound represented by formula (II), and a tautomer and pharmaceutically acceptable salt of same. 

S1P1 agonist and application thereof

Growing community of inventors

Shanghai, China

Lingyun Wu